Rebirth of Hong Kong 1981

  Chapter 710 Perfect Medical System

   Whitehead's reminder made Old Jack frown. The government intends to promote the domestic pharmaceutical industry to develop into large companies. He also heard some rumors earlier.

   is about self-interest and no one will ignore it.

   And he also knows that the second largest shareholder of the company wants to gain control of the company for this reason.

   Because only after gaining control of the company can we decide which way the company should take next.

  Since the government intends to promote it, there are only two ways for Shire to go, one is to merge with other pharmaceutical companies, and the other is to wait to be merged by other pharmaceutical companies.

   Whether the two are merged or merged, there are great benefits to be drawn in the middle.

  Because Old Jack is the founder of the company and has increased his status as a shareholder, and directly controls the research laboratory, he has great prestige within the company, so he has been able to support it until now, and he has not been successful in the conspiracy of the second largest shareholder.

  Whitehead, as a Wall Street elite, is the one who knows the top-level decision-making of the government best. Since the other party said so, it means that it is the general trend.

   Although Old Jack is old, he has no problem with his brain. He still knows the truth that if you don't advance, you will retreat.

   If Shire continues to remain the same, it will be overtaken by the pharmaceutical companies around it sooner or later. Once large interest groups are formed, the interests of small and medium-sized enterprises will be compressed to the extreme.

   At that time, the breach of power was minor, and the company might have to be acquired by outsiders.

  Old Jack was silent for a while, and then said, "Heit, I understand what you mean, I will seriously consider this matter when I go back, and maybe I need to trouble you."

   After the completion of Orange Technology’s listing, Goldman Sachs has reaped a reputation and tens of billions of dollars in financing. Even in the United States, a country where there are many financial investment banks, few companies can be found.

   In recent years, many foreign businessmen have raised a wave of investment in the US market. After this battle, those foreign companies that want to list in the US, needless to say, will definitely think of Goldman Sachs for the first time.

   Goldman Sachs became famous in the first battle, and Whitehead, a senior partner of Goldman Sachs, naturally rose with the tide.

   Seeing that Old Jack's face softened, Whitehead finally let go of his heart and said quickly, "Uncle, your business is mine. If you need it, you can contact me at any time."

   "However, I think uncle, if you are interested in expanding the scale of the Shire company, then you should never forget the big moneymaker sitting next to you now."

   "Press?" Old Jack was stunned for a moment, then followed Whitehead's line of sight, and saw Yang Chen drinking wine silently, as if he didn't hear the conversation between the two, and he didn't pick up.

   After Whitehead's reminder, Old Jack quickly understood what he meant, and his gaze towards Yang Chen was a little different.

Seeing that Yang Chen didn't respond, Whitehead continued: "As far as I know, Yang has invested in quite a few American pharmaceutical companies, including several well-known pharmaceutical companies. The stocks he holds have already Enough to get into the board of directors and participate in the shareholders' decision-making meeting."

   "If Uncle wants to raise money, he can raise money internally first. I don't think Yang will reduce the shares he holds, and even increase his shares."

   Whitehead's tone of voice was very positive, obviously he was sure that Yang Chen would not give up Shire Pharmaceuticals.

"Cough cough" Hearing this, Yang Chen glared at Whitehead angrily, with a somewhat sarcastic tone, and said, "Whitehead, you are enough of a Wall Street elite, and you are ready to transfer to school to become a priest. , right?"

  Whitehead didn't argue, and said straight: "Yang, you don't actually say it, I also know that the purpose of your investment in so many pharmaceutical companies in the United States is not for holding shares or participating in the company's internal management."

   "Your target is in Asia, not the United States. You and your uncle can be said to have no conflict of interest. In this case, why can't we cooperate further?"

  Yang Chen didn't answer, because the other party was right, he invested in a US pharmaceutical company, and he never thought about controlling it or participating in their internal management.

   Of course, even if he thought about it, in general, the U.S. government would not allow foreign investors to control a well-known pharmaceutical company like Shire.

  The medical system is related to the lives and health of the American people. To let foreign companies control it is to hand over the lives and health of hundreds of millions of people in the United States to outsiders.

   This is absolutely not allowed to happen to Americans.

  The U.S. publicity has always emphasized how open and free it is. However, in fact, the protection of some sensitive industries and companies in the United States is unmatched by any country in the world.

  Later Americans often use the words "endangering national security" to impose various restrictions on foreign businessmen, which can be said to be unfavorable wherever they go.

  The United States is now preparing to vigorously promote the domestic pharmaceutical industry, and naturally it will not allow its own pharmaceutical companies to be controlled by foreign investors.

  Yang Chen has invested in many pharmaceutical companies in the United States. In addition to waiting for the stocks of these pharmaceutical companies to appreciate in value, the other is to take this opportunity to obtain the medical achievements of the companies he has invested in.

  Compared with the mature and stable pharmaceutical market in the United States, it has a great role in promoting drug research and development. Due to the developing state in Asia, various problems generally exist in the pharmaceutical industry.

  The research and development of medicine requires a lot of time and money, and also requires a large number of R&D personnel.

   Cultivating a pharmaceutical R&D team is not something that happens overnight.

  Although Asia accounts for nearly two-thirds of the world's population, its pharmaceutical industry is really no way to compare with the United States.

  The United States is a highly developed country with a large population and a well-established health insurance system, which gives American pharmaceutical companies the market they need.

   With a lucrative market return, US pharmaceutical companies can increase their R&D efforts, a virtuous cycle that most countries in Asia lack.

  The United States is the most successful country to implement a free pricing system. The price of medicine is mainly determined by the overall trend of market supply and demand.

  The pricing mechanism in the United States gives pharmaceutical companies greater pricing autonomy, especially companies with monopoly products, which basically enjoy monopoly pricing power.

   The biggest advantage of this system is that it can effectively promote the speed and intensity of drug research and development.

  Although later generations in the United States also had great voices against high drug prices, this voice did not cause much social problems, which is mainly due to the relatively sound medical insurance system in the United States.

  The United States has a mature medical insurance market, and the wide coverage of medical insurance reduces the proportion of patients’ out-of-pocket expenses, which in turn reduces the sensitivity of the demand side to drug prices.

  ——

   (end of this chapter)